ten23 health AG
ten23 health AG, headquartered in Switzerland (CH), is a pioneering company in the biopharmaceutical industry, specialising in the development of innovative drug delivery systems. Founded in 2020, ten23 health has quickly established itself as a leader in the field, focusing on the creation of unique formulations that enhance the efficacy and safety of therapeutic agents. With a strong operational presence across Europe, ten23 health AG offers a range of core services, including formulation development, analytical services, and regulatory support. Their commitment to advancing drug delivery technologies sets them apart, enabling clients to navigate complex challenges in the pharmaceutical landscape. Recognised for their expertise and innovative solutions, ten23 health continues to make significant strides in improving patient outcomes and solidifying their market position.
DitchCarbon Score
How does ten23 health AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ten23 health AG's score of 60 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ten23 health AG's reported carbon emissions
In 2024, ten23 health AG reported total carbon emissions of approximately 13,044,500 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 99% of the total. Specifically, Scope 1 emissions were 700 kg CO2e, while Scope 2 emissions were reported at 86,300 kg CO2e (market-based). The previous year, 2023, saw total emissions of approximately 15,423,300 kg CO2e, with Scope 1 at 500 kg CO2e and Scope 2 at 112,700 kg CO2e (market-based). The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030 from a 2023 baseline. Additionally, ten23 health AG is committed to achieving net-zero emissions by 2050 and plans to reduce total emissions (Scope 1, 2, and 3) by 90% by the same year. These targets have been validated by the Science Based Targets initiative (SBTi) and align with the goal of limiting global warming to 1.5°C. Overall, ten23 health AG's emissions strategy reflects a strong commitment to sustainability and climate action, particularly in the pharmaceutical and biotechnology sector, where reducing carbon footprints is increasingly critical.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | 000 | 000 | 000 |
| Scope 2 | 115,600 | 000,000 | 000,000 | 00,000 |
| Scope 3 | 282,900 | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ten23 health AG is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
